Tin tức & Cập nhật
Xem bài viết Tim mạch
Xem
Chỉ hiển thị Multimedia

Insights from latest CCS & ACS guidelines on lipid management
05 Jun 2025
bởiKanas Chan
The advent of new lipid-lowering agents, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has led to guideline updates on management of chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). In addition to potent LDL-cholesterol (LDL-C) reduction, alirocumab may mitigate atherosclerotic cardiovascular disease (ASCVD) risk by inducing plaque stabilization and exerting protective vascular effects.
05 Jun 2025








